SCHEMBL9959549

SCHEMBL9959549

COc1ccc2c(c1)c(Cc1ccc(Cl)cc1)c(C)n2Cc1ccc(Cl)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.73
CYP1A2 P05177 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2C9 P11712 2/20 0.73
TSHR P16473 2/20 0.73
CYP2C19 P33261 2/20 0.73
PMP22 Q01453 2/20 0.73
MEN1 O00255 1/20 0.73
RGS12 O14924 1/20 0.73
ALDH1A1 P00352 1/20 0.73
MAPT P10636 1/20 0.73
PKM P14618 1/20 0.73
NFKB1 P19838 1/20 0.73
MAPK1 P28482 1/20 0.73
GNAI1 P63096 1/20 0.73
KMT2A Q03164 1/20 0.73
HIF1A Q16665 1/20 0.73
PLA2G2A P14555 9/20 0.67
PPARG P37231 2/20 0.60
PTGS2 P35354 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872387 0.86 LMNA (0.69) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL3889556 0.86 LMNA (0.72) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL10627225 0.85 MAPT (0.67) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL9959499 0.84 LMNA (0.63) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL1322507 0.84 LMNA (1.00) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL8899480 0.84 LMNA (0.66) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL9958996 0.84 LMNA (0.53) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL8292280 0.82 LMNA (0.78) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL3248500 0.81 LMNA (0.74) LMNACYP1A2CYP3A4CYP2C9TSHR
SCHEMBL8300729 0.81 PLA2G2A (1.00) LMNACYP1A2CYP3A4CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657012-B2 FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-23 US disclosed
EP-2655356-B1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS INC (US) 2016-08-03 EP disclosed
US-20150175599-A1 FAAH Inhibitors IRONWOOD PHARMACEUTICALS, INC. (US) 2015-06-25 US disclosed
EP-2655356-A1 FAAH INHIBITORS Ironwood Pharmaceuticals, Inc. (US) 2013-10-30 EP disclosed
WO-2012088469-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175599-A1 FAAH Inhibitors FAAH, FAAH2, ASAH1 LMNA 3608/4885CYP1A2 427/4885CYP3A4 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.